Year: 2010
Opponents of New Federal Health Care Law Wage Constitutional War Against It in Courts
New WLF Paper Details Below-the-Radar Foreign Regulatory Threats to U.S. High Tech
Economic growth and job creation in the United States today relies heavily upon expansion and innovation from industries which develop and commercialize highly complex technology. Enterprises and entrepreneurs in these industries require constant access to capital, and investors who can provide such financial resources must consider the potential risks and rewards. The creation of new … Continued
Last Week at WLF
Litigation Updates: In re Securities & Exchange Commission Proposed Whistleblower Rules On December 17, 2010, WLF urged the Securities & Exchange Commission (SEC) to revise its proposed rules for implementing a new whistleblower law, before issuing them in final form. In formal comments filed with the SEC, WLF expressed a longstanding interest in the work … Continued
Finger on the Pulse: From Our Blogroll and Beyond
Plaintiffs in private antitrust suit challenging “reverse payment” drug patent settlements petitions the Supreme Court. Will FTC amicus brief follow? (FDA Law Blog) So many say so much about Center for Science in the Public Interest’s “Happy Meal suit” (Overlawyered) Professor Ribstein on enduring difficulties with SEC’s Regulation FD (featuring cite to his 2000 WLF … Continued
Respect for Fundamental Freedoms Inspires U.S. Philanthropy at Its Best
As we enter the critical final two weeks of the year’s most important month for non-profit institutions which rely upon donations,* now is a good time to reflect upon the fundamental freedoms that allow Americans to be the world’s most charitable people, and contemplate why those freedoms are increasingly threatened. The ability to choose freely from the … Continued
SEC Urged To Revise Proposed Whistleblower Rules
First Amendment Implications Of Arizona Immigration Law
By Calli Bailey, a 2010 Judge K.K. Legett Fellow at Washington Legal Foundation who is a third year law student at Texas Tech University.
FDA’s 510(k) Working Group Report: How Will It Affect Medical Device Innovation?
By Neil F. O’Flaherty, a principal with the law firm of Olsson Frank Weeda Terman Bode Matz PC.
“False Patent Marking” Qui Tam Lawsuits Are Constitutionally Suspect
By Adam H. Charnes, a partner, and Chad D. Hansen, an associate, in the Winston-Salem, North Carolina, office of Kilpatrick Stockton LLP.